2018年肺癌靶向治疗与免疫治疗的临床试验进展
Advances in clinical trials of targeted therapy and immunotherapy of lung cancer in 2018.
作者信息
Hu Zhengyang, Li Ming, Chen Zhencong, Zhan Cheng, Lin Zongwu, Wang Qun
机构信息
Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
出版信息
Transl Lung Cancer Res. 2019 Dec;8(6):1091-1106. doi: 10.21037/tlcr.2019.10.17.
Abstract
There were many clinical studies on lung cancer in 2018. In particular, significant progress has been made in immunotherapy and targeted therapy. Whether in small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC), immune checkpoint inhibitors (ICIs) have shown good results. For patients with specific gene mutations, the new generation inhibitors also showed good results in clinical trials. In this review, we summarize the clinical trials in lung cancer in 2018 and describe the progress and prospects for lung cancer therapies.
摘要
2018年有许多关于肺癌的临床研究。特别是在免疫治疗和靶向治疗方面取得了重大进展。无论是在小细胞肺癌（SCLC）还是非小细胞肺癌（NSCLC）中，免疫检查点抑制剂（ICIs）都显示出了良好的效果。对于具有特定基因突变的患者，新一代抑制剂在临床试验中也显示出了良好的效果。在这篇综述中，我们总结了2018年肺癌的临床试验，并描述了肺癌治疗的进展和前景。
相似文献
1
Advances in clinical trials of targeted therapy and immunotherapy of lung cancer in 2018.2018年肺癌靶向治疗与免疫治疗的临床试验进展
Transl Lung Cancer Res. 2019 Dec;8(6):1091-1106. doi: 10.21037/tlcr.2019.10.17.
2
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.PD-1/PD-L1 阻断疗法在晚期非小细胞肺癌中的应用：现状与未来方向。
Oncologist. 2019 Feb;24(Suppl 1):S31-S41. doi: 10.1634/theoncologist.2019-IO-S1-s05.
3
Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.利用靶向下一代测序技术来描述小细胞肺癌的肿瘤突变负担和免疫检查点抑制的疗效。
J Immunother Cancer. 2019 Mar 28;7(1):87. doi: 10.1186/s40425-019-0572-6.
4
Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).非小细胞肺癌（NSCLC）中的免疫检查点抑制剂（ICIs）。
J UOEH. 2018;40(2):173-189. doi: 10.7888/juoeh.40.173.
5
Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.免疫检查点阻断作为非小细胞肺癌的潜在治疗靶点。
Expert Opin Biol Ther. 2016 Oct;16(10):1209-23. doi: 10.1080/14712598.2016.1214265. Epub 2016 Aug 5.
6
Prospects of targeted and immune therapies in SCLC.小细胞肺癌的靶向和免疫治疗前景。
Expert Rev Anticancer Ther. 2019 Feb;19(2):151-167. doi: 10.1080/14737140.2019.1559057. Epub 2018 Dec 28.
7
Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer.非小细胞肺癌的分子机制和靶向治疗包括免疫疗法。
Curr Cancer Drug Targets. 2019;19(8):595-630. doi: 10.2174/1568009619666181210114559.
8
Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questions.免疫检查点抑制剂在非小细胞肺癌（NSCLC）中的应用：特殊亚组人群方法和未解决的热点问题。
Cancer Treat Rev. 2018 Mar;64:21-29. doi: 10.1016/j.ctrv.2018.02.002. Epub 2018 Feb 8.
9
Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter?免疫衰老与非小细胞肺癌患者的免疫检查点抑制剂：年龄真的重要吗？
Cancer Treat Rev. 2017 Nov;60:60-68. doi: 10.1016/j.ctrv.2017.08.003. Epub 2017 Aug 24.
10
[Clinical Research Progress of Immune Checkpoint Inhibitors in the Treatment of
Small Cell Lung Cancer].免疫检查点抑制剂治疗小细胞肺癌的临床研究进展
Zhongguo Fei Ai Za Zhi. 2019 Apr 20;22(4):239-244. doi: 10.3779/j.issn.1009-3419.2019.04.07.
引用本文的文献
1
Tocilizumab and CytoSorb for delayed severe cytokine release syndrome after ipilimumab plus nivolumab immunotherapy.托珠单抗和细胞因子吸附剂用于治疗伊匹单抗联合纳武利尤单抗免疫治疗后迟发性严重细胞因子释放综合征。
Immunotherapy. 2024;16(12):791-801. doi: 10.1080/1750743X.2024.2370180. Epub 2024 Jul 17.
2
The radiological characteristics, tertiary lymphoid structures, and survival status associated with EGFR mutation in patients with subsolid nodules like stage I-II LUAD.亚实性肺结节（Ⅰ-Ⅱ期 LUAD）患者中与 EGFR 突变相关的放射学特征、三级淋巴结构和生存状态。
BMC Cancer. 2024 Mar 25;24(1):372. doi: 10.1186/s12885-024-12136-6.
3
Propyl gallate induces cell death in human pulmonary fibroblast through increasing reactive oxygen species levels and depleting glutathione.没食子酸丙酯通过增加活性氧水平和消耗谷胱甘肽诱导人肺成纤维细胞死亡。
Sci Rep. 2024 Mar 5;14(1):5375. doi: 10.1038/s41598-024-52849-z.
4
IL6-STAT3-C/EBPβ-IL6 positive feedback loop in tumor-associated macrophages promotes the EMT and metastasis of lung adenocarcinoma.肿瘤相关巨噬细胞中的 IL6-STAT3-C/EBPβ-IL6 正反馈环促进肺腺癌的 EMT 和转移。
J Exp Clin Cancer Res. 2024 Feb 29;43(1):63. doi: 10.1186/s13046-024-02989-x.
5
Propyl gallate induces human pulmonary fibroblast cell death through the regulation of Bax and caspase-3.棓丙酯通过调控Bax和半胱天冬酶-3诱导人肺成纤维细胞死亡。
Ann Med. 2024 Dec;56(1):2319853. doi: 10.1080/07853890.2024.2319853. Epub 2024 Feb 19.
6
Non-Coding RNAs as Key Regulators in Lung Cancer.非编码 RNA 作为肺癌的关键调控因子。
Int J Mol Sci. 2023 Dec 31;25(1):560. doi: 10.3390/ijms25010560.
7
Ebselen Inhibits the Growth of Lung Cancer Cells via Cell Cycle Arrest and Cell Death Accompanied by Glutathione Depletion.依布硒啉通过细胞周期阻滞和谷胱甘肽耗竭诱导的细胞死亡抑制肺癌细胞生长。
Molecules. 2023 Sep 6;28(18):6472. doi: 10.3390/molecules28186472.
8
Construction and validation of a novel prognostic nomogram for predicting overall survival in lung adenocarcinoma patients with different patterns of metastasis.构建并验证一种新型列线图预测不同转移模式肺腺癌患者总生存的预后模型。
J Cancer Res Clin Oncol. 2023 Nov;149(16):15039-15053. doi: 10.1007/s00432-023-05288-8. Epub 2023 Aug 23.
9
Enhanced recovery of postoperative nursing for single-port thoracoscopic surgery in lung cancer patients.肺癌患者单孔胸腔镜手术术后护理的加速康复
Front Oncol. 2023 May 23;13:1163338. doi: 10.3389/fonc.2023.1163338. eCollection 2023.
10
Dissecting the single-cell transcriptome network of macrophage and identifies a signature to predict prognosis in lung adenocarcinoma.解析巨噬细胞的单细胞转录组网络，并确定一个特征来预测肺腺癌的预后。
Cell Oncol (Dordr). 2023 Oct;46(5):1351-1368. doi: 10.1007/s13402-023-00816-7. Epub 2023 Apr 20.
本文引用的文献
1
Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor.洛拉替尼在先前酪氨酸激酶抑制剂治疗失败的伴有ALK 或 ROS1 重排的韩国非小细胞肺癌患者中的疗效和安全性。
Clin Lung Cancer. 2019 May;20(3):215-221. doi: 10.1016/j.cllc.2018.12.020. Epub 2018 Dec 31.
2
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.洛拉替尼治疗 ALK 阳性非小细胞肺癌患者的疗效：一项全球性 2 期研究结果。
Lancet Oncol. 2018 Dec;19(12):1654-1667. doi: 10.1016/S1470-2045(18)30649-1. Epub 2018 Nov 6.
3
Hyperprogressive disease: recognizing a novel pattern to improve patient management.Hyperprogressive disease：认识一种新的模式以改善患者管理。
Nat Rev Clin Oncol. 2018 Dec;15(12):748-762. doi: 10.1038/s41571-018-0111-2.
4
Real-world anaplastic lymphoma kinase (ALK) rearrangement testing patterns, treatment sequences, and survival of ALK inhibitor-treated patients.真实世界间变性淋巴瘤激酶（ALK）重排检测模式、ALK 抑制剂治疗患者的治疗顺序和生存情况。
Curr Med Res Opin. 2019 Mar;35(3):535-542. doi: 10.1080/03007995.2018.1533458. Epub 2018 Nov 9.
5
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.度伐利尤单抗化疗和放疗后用于 III 期非小细胞肺癌的总生存。
N Engl J Med. 2018 Dec 13;379(24):2342-2350. doi: 10.1056/NEJMoa1809697. Epub 2018 Sep 25.
6
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.布加替尼与克唑替尼用于治疗间变性淋巴瘤激酶阳性的非小细胞肺癌。
N Engl J Med. 2018 Nov 22;379(21):2027-2039. doi: 10.1056/NEJMoa1810171. Epub 2018 Sep 25.
7
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.阿替利珠单抗联合化疗一线治疗广泛期小细胞肺癌。
N Engl J Med. 2018 Dec 6;379(23):2220-2229. doi: 10.1056/NEJMoa1809064. Epub 2018 Sep 25.
8
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗用于鳞状非小细胞肺癌。
N Engl J Med. 2018 Nov 22;379(21):2040-2051. doi: 10.1056/NEJMoa1810865. Epub 2018 Sep 25.
9
Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations.表皮生长因子受体基因突变的非小细胞肺癌患者一线使用吉非替尼治疗后复发时使用吉非替尼联合培美曲塞的 II 期临床试验。
Lung Cancer. 2018 Oct;124:65-70. doi: 10.1016/j.lungcan.2018.07.031. Epub 2018 Jul 23.
10
Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study.阿来替尼对比克唑替尼用于治疗初治的间变性淋巴瘤激酶阳性（ALK+）非小细胞肺癌：来自 ALEX 研究的中枢神经系统疗效结果。
Ann Oncol. 2018 Nov 1;29(11):2214-2222. doi: 10.1093/annonc/mdy405.
Zotero 插件